secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125331
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance
--------------------------------------------------------------------------------

- Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).
- GAAP net income $12.3M ($0.09 diluted EPS) vs $3.2M ($0.02) YoY.
- Adjusted EBITDA $13.4M, down from $16.0M; Non-GAAP operating income $7.1M vs $11.0M.
- Cash $94.9M, net debt $62.1M; FY guidance: rev $455-480M, adj net income $6.7-18.4M.
- CEO cites brand equity and work with policymakers on access solution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017024125331/0000950170-24-125331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017024125331/orgo-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer